Merck + Co., Inc.

Jacquelynn J Cook

George D Hartman

Melissa S Egbertson

Robert J Gould

Frederic L Sax

Steve D Young

A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.

Platelet aggregation inhibition using low molecular weight heparin in

Fibrinogen receptor antagonist prodrugs having the structure, for example, of ##STR1## more particularly, ##STR2##

Growing community of inventors

Collegeville, PA, United States of America

Jacquelynn J Cook